INSIGHTS ON CLINICAL TRIAL PARTNERING

• Targeted Modalities: Trends, Challenges, CDMO Considerations

  Targeted modalities are designed to bind specifically to receptors or biological targets, ensuring a more directed and effective treatment while reducing systemic exposure and unintended side-effects.

• From Budgets To Payments

  Global site payments bring lump-sum invoices, multiple languages, and VAT complexity. Discover how streamlined financial workflows reduce risk and delay.

• We Help Sites Coordinate Payments, Travel, And Participant Support

  Splitting payments, travel, and participant services can add work for sites. See how a connected model eases coordination and gives participants clearer support.

• Expedite Drug Development With An Integrated CDMO-CRO Model

  From optimizing first-in-human strategies to leveraging AI-enabled digital architectures, the integrated CDMO-CRO services model reduces risk and maximizes program value.

• Selecting The Right Site Payments Solution For Today's Clinical Trials: What To Look For

  6/4/2026

  Are you managing site payments with spreadsheets and manual processes? Discover how automation can reduce administrative burden, improve site relationships, and accelerate clinical trial operations.

• Breaking Free From Process Paralysis In Clinical Trials

  1/13/2025

  Explore the implementation of CRIO’s eSource solution by a leading pharmaceutical company to overcome process paralysis in clinical research.

• The New Blueprint For Oncology Trials: Agility, Consistency, & Scale

  6/3/2026

  Oncology trials are increasingly complex, exposing gaps in traditional operations; consistency, scalability, and agility help teams adapt faster and reduce inefficiencies.

• Creating Operational Efficiency And Competitive Edge

  9/10/2025

  Site networks offer a strategic approach to oncology clinical trials by accelerating study startup and expanding access to diverse patient populations.

• Tailored Approach Supports Bladder Cancer Breakthrough

  3/5/2026

  Discover how a flexible operational strategy and expert site management help bladder cancer programs overcome complex logistical hurdles and achieve critical regulatory milestones.